Core Insights - Ono Pharmaceutical Co., Ltd. announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib for patients with TGCT where surgical removal is not an option [1] Group 1 - The results will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO) scheduled for October 17-21 in Berlin, Germany [1]